Related to VolitionRX to Test Its Cancer Diagnostics Platform with Abcodia’s Biobank

• Clinical Reference Sets Up U.K. Lab along with Quotient Bioresearch
  
• Warnex Develops Test to Detect Swine Flu Virus Mutation Linked to Tamiflu Resistance
  
• Facet Biotech Steps Up to Help Trubion Advance Early-Stage Anticancer Agent with a $20M Fee
  
• Scientists Uncover Molecular Pathway that Makes Tumors More Aggressive
  
• Rosetta's miRNA-Based Cancer Tests Break Into European Market through Distribution Deal with AXA
  
• PerkinElmer Makes Two Acquisitions to Pad Diagnostics Business in Emerging Markets
  
• Qiagen Releases Influenza A/H1N1 Detection Kit for Research Purposes
  
• BioMarker Strategies Secures $1.7M to Expedite Live Tumor Cell Testing System
  
• Access Pharma Taps Accupac to Manufacture Oral Mucositis Therapy in North America
  
• Karus Taps Queen Mary, University of London's Expertise for PI3K Inhibitor Development
  
• Altor Scores $3M NCI Grant for Clinical Development of IL-2 Boosting Drug
  
• Roche Sequence Capture and Genome Sequencing Technologies to Be Evaluated for Cancer Genetics
  
• Sanofi-Aventis Gains License to Phase I Anticancer Agent from Merrimack for $60M Up Front
  
• Researchers Link Anticancer Activity of Actinomycin D with NEDDylation Inhibition
  
• YM BioSciences to Take Over Cytopia Gaining Base in Australia
  
• Gen-Probe to Pay $60M in Prodesse Buyout
  
• Spirogen Receives About $24M for Clinical-Stage Anticancer Drug and Reacquires Development Rights
  
• Transgenomic Licenses Cold-PCR Technology from the Dana-Farber Cancer Institute
  
• TargetEx Takes Over Coordinating European CancerGrid Project
  
• Bayer Decides to Investigate Compugen’s Newly Discover Cancer Targets